Albani F, Tamè M R, De Palma R, Bernardi M
Laboratory of Neuropharmacology, Institute of Clinical Neurology, Bologna, Italy.
Eur J Clin Pharmacol. 1991;40(4):423-5. doi: 10.1007/BF00265857.
The pharmacokinetics of metoclopramide has been studied after acute IV administration to 12 patients with hepatic cirrhosis (6 with and 6 without ascites) and 6 control subjects. The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respectively, vs 6.4 h in controls). Total plasma clearance was significantly lower in patients (0.29 and 0.36 l.kg-1.h-1 vs 0.52 l.kg-1.h-1 in controls). The differences between patients with and without ascites did not reach statistical significance. Reduction of functional hepatic blood flow in cirrhotic patients is the probable cause of the observed alteration in metoclopramide kinetics.
对12例肝硬化患者(6例有腹水,6例无腹水)和6例对照受试者进行急性静脉注射后,研究了甲氧氯普胺的药代动力学。患者的消除半衰期显著延长(有腹水和无腹水患者分别为11.4小时和9.9小时,而对照组为6.4小时)。患者的总血浆清除率显著降低(分别为0.29和0.36升·千克⁻¹·小时⁻¹,而对照组为0.52升·千克⁻¹·小时⁻¹)。有腹水和无腹水患者之间的差异未达到统计学意义。肝硬化患者功能性肝血流减少可能是观察到的甲氧氯普胺动力学改变的原因。